Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tim, R. W.
Right arrow Articles by Sanders, D. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tim, R. W.
Right arrow Articles by Sanders, D. B.
Neurology 2000;54:2176-2178
© 2000 American Academy of Neurology
Brief Communications

Lambert-Eaton myasthenic syndrome: Electrodiagnostic findings and response to treatment

Richard W. Tim, MD, Janice M. Massey, MD and Donald B. Sanders, MD

From the Duke University Medical Center, Durham, NC.

Address correspondence and reprint requests to Dr. Richard W. Tim, Box 31105, Duke University Medical Center, Durham, NC 27710; e-mail: rtim{at}acpub.duke.edu

The authors reviewed the incidence of cancer, repetitive nerve stimulation findings, and response to treatment in 73 patients with Lambert-Eaton myasthenic syndrome. Thirty-one patients (42%) had lung cancer, 29 small cell. Doubling of the compound motor action potential amplitude in three tested distal muscles was seen in only 41% of patients. Treatment with 3,4-diaminopyridine produced moderate to marked self-reported functional improvement in 79% of the 53 treated patients.

Key words: Lambert-Eaton myasthenic syndrome—Repetitive nerve stimulation—Small cell lung cancer—Paraneoplastic syndrome—3—4-Diaminopyridine.




This article has been cited by other articles:


Home page
 JCOHome page
M. J. Titulaer, P. W. Wirtz, L. N.A. Willems, K. W. van Kralingen, P. A.E. S. Smitt, and J. J.G.M. Verschuuren
Screening for Small-Cell Lung Cancer: A Follow-Up Study of Patients With Lambert-Eaton Myasthenic Syndrome
J. Clin. Oncol., September 10, 2008; 26(26): 4276 - 4281.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
N. P. Hirsch
Neuromuscular junction in health and disease
Br. J. Anaesth., July 1, 2007; 99(1): 132 - 138.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
P. W. Wirtz, J. G. van Dijk, P. A. van Doorn, B. G.M. van Engelen, A. J. van der Kooi, J. B. Kuks, A. Twijnstra, M. de Visser, L. H. Visser, J. H. Wokke, et al.
The epidemiology of the Lambert-Eaton myasthenic syndrome in the Netherlands
Neurology, July 27, 2004; 63(2): 397 - 398.
[Full Text] [PDF]

Home page
 BrainHome page
F. Graus, F. Keime-Guibert, R. Rene, B. Benyahia, T. Ribalta, C. Ascaso, G. Escaramis, and J. Y. Delattre
Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients
Brain, June 1, 2001; 124(6): 1138 - 1148.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by AAN Enterprises, Inc.